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 ABSTRACT 
Hypertension (high blood pressure) is a multifactorial condition that remains a big 
worldwide problem. 95% of all hypertensive people suffer from essential hypertension 
with unknown causes. This can cause different heart diseases such as cardiac 
hypertrophy (CH), a condition which can ultimately lead to heart failure. Salt intake 
has been suggested to be one of the factors promoting hypertension. The aims of this 
thesis were to elucidate the importance of salt-inducible kinase 1 (SIK1) in the 
development of high blood pressure (BP) and to identify salt-activated molecular 
pathways that could activate transcription factors and genes coupled with development 
of CH independently of high BP.  
 
SIK1 has been implicated in intracellular pathways that control cell sodium 
homeostasis and is also important for myocyte development. To investigate whether 
SIK1 is a potential regulator of BP, genotype-phenotype association studies between a 
genetic variation within SIK1 coding region (rs3746951) and BP in four population-
based cohorts were performed. After performing a meta-analysis of the four studies the 
results revealed an association between the rs3746951 and lower systolic- and diastolic 
blood pressures. Rs3746951 was also associated with lower left ventricular mass. In 
studies performed in cultured vascular smooth muscle cells it was shown that 
rs3746951 was associated with higher SIK1 and Na+/K+-ATPase activity. These results 
suggest that SIK1 affects BP.  
 
To explore the involvement of SIK1 in the development of CH, studies were 
performed in a mouse cardiac atrium cell line (HL-1). The overall results revealed that 
SIK1 mediated the effect of salt on transcription factors MEF2 and NFAT and on the 
genes associated with CH: Mhc Bnp and Ska. Studies performed on samples from 
human biopsies confirmed the association between SIK1 and hypertrophic genes. 
These results suggest that salt intake could trigger events that lead to increased 
expression levels of genes associated with CH, independently of increases in BP and 
that SIK1 is a mediator of this process. 
 
Since SIK1 can affect the transcription of genes that are associated with CH, the 
involvement of a hypertensive form of α-adducin and SIK isoforms in this process was 
examined. mRNA levels for SIK2, α-adducin, and several markers of CH were 
correlated in tissue biopsies obtained from human hearts. Evidence that SIK2 is 
critical for the development of CH in response to chronic high-salt diet was also 
obtained in mice with ablation of the Sik2 gene. Increases in heart size upon high salt 
diet, occurred only in Sik2+/+ but not in Sik2-/- mice. The presence of a hypertensive 
variant of α-adducin in Milan rats (before they become hypertensive) was associated 
with elevated transcription factors and genes associated with CH. Thus, we concluded 
that CH, triggered by salt intake or the presence of a genetic variant of α-adducin, 
requires SIK2 and is independent of elevated BP. 
 
Taken together, this thesis describes how the SIK network could affect BP regulation 
and independently of BP mediate the effect of salt on the development of CH. 
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1 INTRODUCTION 
Hypertension, a raise in arterial blood pressure (BP), remains a big worldwide problem 
and is a major factor contributing to the development of cardiovascular diseases such as 
cardiac hypertrophy (CH). Despite recent advances in understanding risk factors and 
pathophysiology behind this condition, hypertension prevalence continues to increase. 
From data based on the participants from the Framingham Heart Study, untreated 
hypertension has been estimated to shorten the life expectancy with around 5 years 
(Franco, Peeters et al. 2005) for both men and women. As many as 1.56 billion people 
worldwide may be affected by the year 2025 (2007) and developing countries in Africa 
and Asia and western countries with fully developed healthcare systems are affected.  
 
Around 95% (Cowley 2006) of all people having high BP have unknown cause of the 
disease which is classified as essential (primary) hypertension. Secondary causes, such 
as renal failure, monogenic causes or aldosteronism, among others, comprise the 
secondary form of hypertension (Carretero and Oparil 2000). Lifestyle factors such as 
alcohol, tobacco consumption, a salt-rich diet, processed or fatty foods in combination 
with environmental and genetic factors have been associated with the development of 
primary hypertension (Mullins, Bailey et al. 2006). In developed countries, physical 
inactivity and high salt diet are thought to be the among biggest contributors to 
development of primary hypertension (Carretero and Oparil 2000). Despite the 
availability of a variety of antihypertensive drugs, the prevalence of hypertension 
increases even in the developed countries where the drug cost is rarely a problem. 
1.1 CARDIAC HYPERTROPHY 
One of the major complications of sustained elevated BP is CH, which refers to the 
enlargement of the myocardium. At the cellular level, this is characterized by increased 
activity of a variety of transcription factors, increased transcription of genes associated 
with CH, altered gene expression profile and increased protein synthesis which leads to 
larger cell size and eventually to CH. Pathological CH causes a change in heart 
geometry which leads to reduced cardiac function, fibrosis and could ultimately lead to 
heart failure. The intracellular signaling pathways leading to development of 
hypertrophy remain poorly understood. 
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1.2 HYPERTENSION 
 
The most common definition of hypertension is when after two consecutive visits to a 
doctor or after two subsequent measurements the systolic blood pressure is ≥140 mm 
Hg and/or diastolic blood pressure is ≥90 mm Hg (Carretero and Oparil 2000). In 
western countries, systolic blood pressure (SBP) tends to rise with age leading to a 
prevalence of systolic hypertension in industrialized countries (Carretero and Oparil 
2000). BP tends to vary among ethnical groups. For instance in US, black subjects have 
the highest prevalence of high BP while the Mexican population has the lowest. 
Socioeconomic factors and lifestyle also affect the prevalence and mortality rate of 
people affected with high BP. Other factors, such as gender and geographic location 
also have effect on BP prevalence. 
 
Idiopathic, essential and primary hypertension, are the terms for same type of 
hypertension, when there is no known cause to high BP. This is the most common type 
of hypertension and accounts for around 95% of all the cases worldwide. Secondary 
hypertension accounts for the remaining cases and is caused by diseases such as renal 
failure, aldosteronism, renovascular disease and endocrine diseases.  
Even though essential hypertension is generally said to have unknown causes there are 
a number of factors affecting development of high BP. These factors are high alcohol 
intake, high sodium intake, obesity and insulin resistance, low potassium or calcium 
intakes and genetic predisposition. These factors by themselves or in combination can 
influence the development of high BP. There have been some studies that point to weak 
associations between polymorphisms in certain genes, such as α-adducin (Manunta, 
Burnier et al. 1999) and essential hypertension.
 
Figure 1. A model of the essential hypertension. Genetic predisposition together with age, 
gender and various environmental factors affect the development of high blood pressure.  
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BP is mainly dependent on two factors: total peripheral resistance and cardiac output 
(Cowley 2006). Cardiac output is in turn dependent of heart rate, heart stroke volume 
extracellular fluid volume, whilst peripheral resistance is dependent on vascular 
function and structural changes in arteries. Hypertension has severe effects on several 
human organs. In the heart the high pressure causes increased workload which could 
lead to hypertrophy, and ultimately to heart failure if left untreated. In the brain the 
increased pressure damages blood vessels causing brain infarction and stroke which 
causes several brain disorders and death. In kidneys the pressure has various effects 
such as nephrosclerosis (Marin, Gorostidi et al. 2005). 
1.3 KIDNEYS AND HYPERTENSION  
 
Kidneys play a major role in BP regulation. When the blood volume increases and the 
vascular resistance remains the same the systemic pressure will also increase. The 
increased pressure will cause kidneys to excrete more fluid and salt. The blood volume 
decreases causing the heart to pump a lesser amount of blood and the arterial pressure 
decreases. In contrast to chemoreceptors, baroreceptors and CNS systems that affect 
short term BP, the fluid based-system controls long term BP levels. Even though 
increased fluid intake affects the blood volume, studies have shown that in fact 
increased sodium intake is the major contributing factor to increased BP because an 
excess of water will be excreted rapidly while salt is harder to excrete. The increased 
sodium levels lead to increased water intake which increase systemic BP. Thus, 
hypertension arises ultimately after kidneys are unable to cope with sodium excretion 
(Guyton 1991). 
While renal diseases can cause secondary hypertension, primary hypertension can 
causes secondary renal diseases. Some of the diseases caused by essential hypertension 
are nephrosclerosis and hypertensive kidney disease (Marin, Gorostidi et al. 2005). 
Hypertension is second only to diabetic nephropathy as a major cause of end stage renal 
disease (Bidani and Griffin 2002). 
1.4 GENETIC PREDISPOSITION  
 
As mentioned previously, 95% of the hypertensive cases are classified as essential or 
primary hypertension. It is estimated that essential hypertension has a heritability of 30-
50%. Therefore it is of importance to find the genes involved in hypertension 
development to help to improve treatment strategies, understand the biochemical 
pathways and recognize individuals that risk developing this disease. So far, very few 
genetic factors that contribute to the development of primary hypertension have been 
identified. The simplest approach to define genes that are affecting BP is by studying 
families or relatives that are affected with hypertension. A detailed linkage analysis can 
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then sometimes reveal the specific locus or even a gene that is affecting the BP. In this 
type of cases when simple Mendelian form is affecting BP, it is mostly due to rare 
genetic disorders (secondary hypertension). Some examples being: Liddle’s syndrome 
when a genetic mutation in the epithelial sodium channel leads to an abnormal re-
absorption of sodium and loss of potassium which leads to hypertension (Lifton, 
Gharavi et al. 2001). Another example is the mutation in peroxisome proliferator-
activated receptor γ (PPARG) which leads to insulin resistance diabetes and 
hypertension (Barroso, Gurnell et al. 1999). These, and a few other mutations giving 
rise to different syndromes and diseases that also give rise to high BP, account for a 
very small percentage of the cases of hypertension. Interestingly, most of the mutations 
causing high BP derived from Mendelian inheritance have been found to, in one way or 
another, be associated with salt re-absorption.  
 
For the essential hypertension, contribution from one single gene is not enough to affect 
the development of hypertension. For this multifactorial disease, small contributions 
from several genes, often coupled with different environmental factors and random 
genetic variations within these genes, lead to high BP development. The effect of the 
genes contributing to elevated pressure could also be modified by other unrelated 
genes. Genome-wide association studies (GWAS) and candidate gene studies have 
been far less successful, often incomplete, or contradictory when identifying genes or 
genetic markers that affect development of hypertension.  
In candidate gene studies a large number of different genotypes are screened at 
chromosome loci of proteins in pathways that are implicated in BP regulation, such as 
the renin-angiotensin-aldosterone (RAAS) system. In GWAS, SNPs are distributed 
throughout the genome, without prior knowledge of the biology of the disease. 
 
Two different studies have reported a linkage of essential hypertension to chromosomes 
2 and 17 (Hsueh, Mitchell et al. 2000; Levy, DeStefano et al. 2000) A recent GWAS 
involving over 200,000 individuals of European descent (Ehret, Munroe et al.) revealed 
new loci associated with BP and confirmed some of previously identified signals from 
GWAS. However, such studies are specific for certain populations or the significance 
threshold for the linkage between genes and hypertension is not reached. Because in 
different GWAS there has not been any particular locus interval repeatedly linked to 
hypertension there might be several loci on different chromosomes that in combination 
together with environmental factors and lifestyle add up small effects on BP ultimately 
affecting the development of hypertension. 
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1.5 HORMONES AND HYPERTENSION 
 
CNS, chemoreceptors, baroreceptors and RAAS system are important in terms of BP 
regulation. Whereas CNS, chemoreceptors and baroreceptors are involved in short-term 
responses (within seconds) to changes in the BP, RAAS is activated within minutes of 
the decreased BP (Guyton 1991). Increased salt intake causes increased thirst and 
higher intake of fluids. This will then affect the RAAS system. RAAS is the hormone 
system that plays a critical role in regulation of BP in human body. In response to lower 
BP renin is released into blood circulation from juxtaglomerular cells in the kidney. 
Circulating renin cleaves angiotensinogen that is produced by the liver to angiotensin I 
(AngI). AngI is then converted to angiotensin II (AngII) by angiotensin converting 
enzyme (ACE) released from capillaries of the lung. AngII has various effects in the 
human body most of which are exerted by binding to angiotensin receptor type I (AT1), 
leading to increased sodium re-absorption in kidneys, vasoconstriction and affecting the 
glomerular filtration rate which increases BP (Unger 2002). In addition, AngII 
stimulates release of the hormone aldosterone which also enhances distal tubule sodium 
re-absorption (Weir and Dzau 1999). Current treatment of hypertension is targeted to 
decreasing the vascular tone using ACE inhibitors as well as AT1 receptor blockers, 
diuretics, β-blockers and calcium channel blockers. The most common method of 
treatment is to use two or more drugs in combination to reduce BP (Paulis and Unger), 
however there is no one-for-all drug strategy and the type of treatment often depends on 
the BP and whether the patient has a specific disease.  
Figure 2. The renin-angiotensin-aldosterone system (RAAS). (+) denotes a stimulatory effect 
 
Increased sodium intake leads to increased release of aldosterone and also stimulates 
production of endogenous ouabain-like factors (OLF). These OLF target the α2 isoform 
of the Na+/K+-ATPase (NK) pumps in the vasculature and in the myocardium, inhibit 
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NK, thereby increasing the vascular tone and myocardium contraction which in turn 
increases BP. This has been shown in rats where low levels of OLF induced 
hypertension. Nanomolar concentrations of circulating endogenous OLF has been 
shown to induce release of AngII in spontaneously hypertensive rats at the same time as 
it induces the release of nitric oxide which has the opposite effect of AngII (Dong, 
Komiyama et al. 2004; Padilha, Rossoni et al. 2004). Recently a novel sodium sensing 
network has been discovered (Sjostrom, Stenstrom et al. 2007). When concentrations of 
sodium raise, a salt-inducible kinase 1 (SIK1) is increased in activity. The increased 
SIK1 activity controls the activity of NK which are involved in sodium homeostasis. 
Interestingly, cells that express the hypertensive form of the α-adducin that causes 
Milan hypertensive rats become spontaneously hypertensive, have also increased SIK1 
activity (Stenstrom, Takemori et al. 2009). With the current advances in OLF and 
sodium signaling research, targeting ouabain-induced intracellular signaling and SIK1 
activity might be effective treatment of hypertension. 
1.6 LIFESTYLE AND ENVIRONMENTAL RISK FACTORS 
 
A number of lifestyle and environmental factors influence the development of 
hypertension. Alcohol, smoking, obesity, diet and stress are all thought to affect BP.  
1.6.1 Alcohol intake 
 
Alcohol elevates both the acute and the chronic BP. Even though the mechanism by 
which alcohol affects BP is not well known, results of studies involving different 
human populations have been consistent and show that alcohol does affect BP. 
Potential mechanisms by which alcohol could affect the BP include the modulation of 
RAAS system, the heart rate and the vascular smooth system (Beilin, Puddey et al. 
1996; Klatsky 1996). It has been shown that refraining from drinking alcohol every day 
lowers BP significantly (Kawano).  
1.6.2 Smoking 
 
It has yet to be established how smoking affects BP. It is has been shown that smoking 
increases acute BP and BP decreases among smokers who have not been smoking for a 
period of time (Minami, Ishimitsu et al. 1999). In contrast, in non-clinical samples non-
smokers and former smokers have significantly higher BP levels than current smokers 
(Lee, Ha et al. 2001; Okubo, Suwazono et al. 2004). However, the general 
recommendation for smokers suffering from hypertension is to quit smoking to 
minimize the CVD mortality risk. 
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1.6.3 Obesity 
 
Both clinical and animal studies point to a strong association between obesity and 
hypertension (Hall 2003). Increases in fat mass, especially increases in visceral adipose 
tissue, lead to increased release of adipocytokines such as endothelin, IL-6, renin, non-
esterified fatty acids and aldosterone that influence development of hypertension (Tilg 
and Moschen 2006; Katagiri, Yamada et al. 2007). Although exact mechanisms 
between obesity and hypertension are not very well understood, obesity induces several 
systems that lead to development of hypertension. Obese individuals have been shown 
to have an increased sympathetic nervous system (SNS) activity (Scherrer, Randin et al. 
1994; Huggett, Burns et al. 2004). Increase in SNS activity indirectly, via activation of 
RAAS system, causes elevated heart rate, increased BP levels and increased renal 
sodium re-absorption. Moreover, high sodium intake that often concurs with high 
calorie intake and obesity further enhances the effect on BP.  
1.6.4 Stress 
 
In a review by Gerin and Lovallo (Lovallo and Gerin 2003) psychological stress was 
defined as “events that challenge the homeostasis of the organism because of their 
perceived threat value, regardless of potential for physical harm“. This includes stress 
from daily job, natural catastrophic events such as earthquakes and tornados, stress of 
speaking publicly or stress derived from fear visiting a doctor (white coat 
hypertension). This acute stress causes transient elevations in BP; however it is yet 
unclear whether this could lead to permanent increases in BP. The European Society of 
Hypertension and The Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure, both state that ‘Lifestyle 
measures should be instituted whenever appropriate in all patients, including subjects 
with high normal blood pressure and patients who require drug treatment (2003; 
Chobanian, Bakris et al. 2003) however, in these recommendations stress handling is 
not included. 
 
It is important to note that many of the environmental factors often are additive, such as 
obesity and alcohol or obesity and smoking. Furthermore, environmental factors 
interact with the genetic factors contributing to the overall chance to develop 
hypertension. Even though in rat models a modification towards healthier lifestyle and 
a healthier diet were not shown to improve the mortality rates, the decrease of the risk 
factors may lead to a lower BP and less hypertensive drug usage avoiding the side-
effects some drugs might induce. 
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1.7 SODIUM AND HYPERTENSION 
 
Salt has only become an important ingredient in our diet over the recent 10.000 years. 
Our ancestors had a diet consisting of less salt intake than 1g/day which means that 
currently we are genetically programmed to handle no more than that amount of salt as 
opposed to today’s worldwide average consumption of 100mmol/day (Brown, Tzoulaki 
et al. 2009). High salt intake has been implicated in the development of hypertension 
and hypertrophy; however there is great inter-individual variation in response to salt 
intake.  
It has been shown that hypertension is strongly associated with salt consumption. In 
modern society the dietary salt intake has increased considerably compared to for 
instance the consumption during the Stone Age. Some tribes in Amazonas who live 
under the same conditions as Stone Age humans have a rich potassium and a minimum 
sodium diet which is approximately 20 times less than the average intake of sodium by 
a person living in a modern developed country. In these tribes there is no hypertension 
observed, suggesting the importance of sodium intake for the development of high BP. 
Epidemiological studies have shown that average sodium intake in developed countries 
should be around half of what it is now. Generally, in populations with low sodium 
intake the prevalence of hypertension is much lower than in populations with high salt 
diet. 
 
Today the average salt intake is more than 3 times of the recommended daily intake. 
Numerous studies, both regional and worldwide, report that there is a correlation 
between salt excretion and BP. The INTERSALT (1988; Stamler, Rose et al. 1991) 
study involving 52 different centers and 10079 individuals, found a significant 
relationship between lower salt intake and a lower systolic BP as well as an association 
between the BP and sodium excretion after adjustment for age. Another worldwide 
study, Cardiovascular diseases and alimentary comparison (CARDIAC) (Yamori, Nara 
et al. 1990), found a significant positive correlation between both systolic- and diastolic 
blood pressures and 24h sodium excretion in men. A recent meta-analysis of 167 
different studies that estimated the effects of low and high sodium intake on BP and the 
different circulating hormones and lipids was performed. In this analysis it was found 
that across the studies in normotensive Caucasians the lower sodium intake caused a 
BP decrease of only 1%, while in hypertensive Caucasians the short term lowering of 
sodium intake decreased the BP with 2-2.5% (Graudal, Hubeck-Graudal et al.). Some 
studies suggest a favorable effect of reduced sodium intake on cardiovascular 
outcomes. For instance, a study examining the long-term effects of sodium reduction 
reported a significantly lower amount of cardiovascular events in the group with 
sodium reduction in the diet compared to the non-intervention group (Cook, Cutler et 
al. 2007). 
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2 COMPLICATIONS OF CHRONIC HYPERTENSION 
 
2.1 RENAL 
 
Hypertension affects the detrimental progression of most end stage renal diseases 
(ESRD) (1998). While hypertension can cause renal diseases, renal diseases can also 
cause hypertension. Kidneys of spontaneously hypertensive rats (SHR) transplanted to 
normotensive recipient rats cause elevated BP and kidneys of normotensive donor rats 
lower BP in SHR rats (Curtis, Luke et al. 1983; Grisk and Rettig 2001). According to 
Guyton (Hall, Guyton et al. 1996) hypertension occurs as a result of the kidneys 
inability to cope with increased sodium intake, meaning that the BP increases in 
response to increased concentrations of sodium.  
 
Because kidneys control most of the sodium homeostasis in humans, they also control 
the BP regulation. BP has been shown to be associated with risk of renal failure, as 
reported in three independent cohort studies (Klag, Whelton et al. 1996; Tozawa, Iseki 
et al. 2003; Hsu, McCulloch et al. 2005). In two of the studies which showed a 
relationship between increased BP and risk of ESRD, renal function was not examined. 
Hsu et al (Hsu, McCulloch et al. 2005) also reported association between BP and 
ESRD, while performing renal function studies. Even small increases in BP were 
significantly associated with the prevalence of ESRD.  
 
The severity of damage inflicted by high BP on kidneys depends on several factors: the 
BP level, how much of the BP load is transmitted to the kidneys and structural 
characteristics of the renal microvasculature which vary between individuals 
(depending on genetic predisposition and previous kidney damage) (Beilin, Goldby et 
al. 1977; Neuringer and Brenner 1993; Bidani and Griffin 2002). To avoid 
complications that may arise in kidney due to high pressure, treatment of hypertension 
involves targeting the RAAS system to reduce BP and to avoid the resulting kidney 
damage (Fogo 2000; Taal and Brenner 2001). This treatment includes ACE blockers 
and ATII receptor antagonists, among others. Because drugs targeted towards RAAS 
system often counteract the natriuresis by lowering the BP, and because salt sensitivity 
increases in damaged kidneys (Johnson, Gordon et al. 1999) a therapy involving drugs 
such as thiazides is sometimes also used in combination with RAAS system inhibitors. 
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2.2 CARDIAC 
 
Cardiac complications arising from chronic hypertension are collectively called 
hypertensive heart diseases (HHD) which includes conditions such as coronary artery 
disease, systolic and diastolic myocardium dysfunctions, arrhythmia and left ventricular 
hypertrophy, among others. According to a meta-analysis of several prospective studies, 
the contribution of hypertension to cardiovascular diseases is greater than any other risk 
factor and even small increases in BP double the risk of ischemic heart disease and 
stroke in people between 40-90 years of age (Lewington, Clarke et al. 2002). Genetic 
predisposition and hypertension are the two of the major factors contributing to the 
development of left ventricular hypertrophy (Levy, Anderson et al. 1988; Galderisi, 
Celentano et al. 1993; Arnett, Hong et al. 2001).  
 
As with any other muscle, increased load on the heart leads to muscle hypertrophy. 
However one should distinguish physiological hypertrophy from pathological 
hypertrophy. Physiological hypertrophy occurs after excessive exercise or pregnancy. 
This form of hypertrophy is reversible and is characterized by enlargement of the left 
ventricular chamber and a uniform increase in ventricular wall and septum. The 
myocyte length increases more than the width by addition of sarcomeres in the middle 
and in the periphery of the myocytes. The proportions between the chamber increase 
and wall increase remain the same and the normal cardiac structure is maintained. This 
does not lead to any abnormal heart function and is a natural adaptation of the heart to 
cope with increased work load. Pathological hypertrophy is not reversible unless treated 
and is characterized by a thickening of the ventricular wall and septum along with 
remodeling and a decreased size of the left ventricular chamber. The width of the 
myocytes is increased more than the length (Heineke and Molkentin 2006).  
 
To increase in size, myocytes have to change the quantitative and qualitative gene 
expression patterns induced by activation of various transcription factors which leads to 
increased protein synthesis. The precise molecular signaling by which hypertension and 
increased mechanical load leads to activation of various intracellular mechanisms and 
eventually to development of CH is not well understood. However, several signaling 
pathways have been suggested. The general consensus is that some of the mechanisms 
leading to increased heart size differ between the pathological and physiological 
hypertrophy.  
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Figure 3. Pathological cardiac hypertrophy. The left ventricle wall and septum are thicker 
compared to the normal heart because of non-uniform addition of sarcomeres.  
 
Mechanical stimuli can initiate increased protein synthesis (Ruwhof and van der Laarse 
2000). This mechanical stress can be accompanied by increased concentration of 
circulating humoral factors (Ruwhof and van der Laarse 2000) although mechanical 
stress alone could also affect growth of the cardiomyocytes (Cooper, Kent et al. 1985). 
This has been proven when blockage of adrenal receptors gave an increased rate of 
protein synthesis (Oi, Haneda et al. 1999) or when isolated cardiomyocytes under 
increased load altered the rate of protein synthesis (Kira, Kochel et al. 1984). It has also 
been shown that stretching cardiomyocytes altered the gene expression profile without 
involvement of humoral factors (Komuro, Kaida et al. 1990; Sadoshima, Jahn et al. 
1992; Kira, Nakaoka et al. 1994). 
 
There are several circulating factors that can initiate growth of cardiomyocytes at the 
cell membrane, such as transforming growth factor-β (TGF-β) AngII, endothelin-1, 
catecholamines (noradrenalin and adrenaline) and insulin growth-like factor-1 (IGF-1) 
(Ruwhof and van der Laarse 2000) (the latter is implicated in the development of 
physiological but not pathological hypertrophy). The release of these humoral factors 
can be triggered by stretching cardiomyocytes, by hemodynamic load or in an autocrine 
fashion. These circulating factors interact with specific target receptors on the cell 
surface that conduct the signal via different intracellular pathways to transcription 
factors which alter the gene expression profile and affect the rate of gene transcription. 
Transcription factors may act alone or interact with one another to co-activate the target 
genes (Akazawa and Komuro 2003). The molecular signaling which leads to activation 
of transcription factors in response to either humoral factors or cell stretching is 
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complex and several intermediate proteins and molecular pathways are involved 
(Heineke and Molkentin 2006).  
 
Two of the transcription factors that have been implicated in development of 
hypertrophy are myocyte enhancer factor 2 (MEF2) and nuclear factor of activated T-
cells (NFAT). As the name suggests, NFAT is a mediator in the t-cell activation, is 
present in a variety of tissues and has five isoforms: NFATc1-c5. Later it was found 
that it also acts as a transcription factor inducing the expression of genes associated 
with hypertrophy. In response to dephosphorylation at the N-terminus by a variety of 
molecules such as calcineurin, NFAT translocates from the cytoplasm to the nucleus 
where it initiates the transcription. NFAT seems to be involved in the regulation of 
pathological but not physiological hypertrophy. Transgenic mice that express activated 
NFAT3 have been shown to develop hypertrophy and heart failure (Molkentin, Lu et al. 
1998). When transgenic mice expressing a luciferase NFAT reporter were subjected to 
both physiological (training) stimuli and pathological (pressure overload) stimuli the 
reporter activity was upregulated only in the mice exposed to pathological stimulus 
(Wilkins, Dai et al. 2004). In addition, inhibition of NFAT in vitro leads to inhibition of 
hypertrophy induced by endothelin-1 and calcineurin (van Rooij, Doevendans et al. 
2002). NFAT is one of the proteins which can interact with other transcription factors 
in order to affect gene transcription. It has been shown that in response to AngII NFAT 
binds to GATA4 to promote BNP gene transcription (Morimoto, Hasegawa et al. 
2001). Moreover, NFAT interacts with MEF2 and enhances MEF2 activity in response 
to calcineurin (van Oort, van Rooij et al. 2006). 
 
MEF2 has a variety of functions in the cell including: muscle generation, tumorigenesis 
and neuronal cell development (Potthoff and Olson 2007). As with NFAT, MEF2 is 
also implicated in the development of CH and is also able to interact with GATA4 to 
enhance transcription of its target genes in a synergistic fashion (Morin, Charron et al. 
2000). MEF2 is controlled by its association with class II histone deacetylases 
(HDAC). Under basal conditions MEF2 activity is inhibited by direct binding of 
HDAC to MEF2 in the nucleus. In response to extracellular stimuli and the subsequent 
increased calcium concentrations, class II HDAC dissociate from MEF2. There are a 
number of kinases that are capable of phosphorylating class II HDAC. SIK1 has been 
shown to be the kinase which phosphorylates class II HDAC. In response to 
catecholamines, CREB enhances the expression of SIK1 which then can affect the 
activity of MEF2 by phosphorylating class II HDAC (Berdeaux, Goebel et al. 2007).  
 
Most models of CH are associated with up-regulation of genes that are now considered 
to be hypertrophic marker genes. These genes include β-myosin heavy chain (β-MHC), 
brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP) and skeletal actin 
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(SkA). As a part of the heart adaptation process, the myosin isoforms undergo a switch 
from the more energy demanding α-MHC to the slower and energy efficient β-MHC 
isoform. The increased expression of the β-MHC have been found in most types of 
hypertension (Palmer 2005). However the switching to the slower isoform eventually 
causes systolic dysfunction. In addition, hypertrophy could lead to a down-regulation of 
certain genes, which also commonly used as markers of CH, namely α-MHC and 
sarcoplasmic reticulum Ca2+-ATPase (SERCA) (McMullen, Shioi et al. 2003). 
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3 SALT-INDUCIBLE KINASE 
 
3.1 THE SIK PROTEIN 
 
Salt-inducible kinases (SIKs) are a family of serine/threonine kinases. Of these, the 
SIK1 is the one most intensively studied. SIK1 is a homolog of sucrose non-fermenting 
like kinase 1 (snf1lk) that has been found in a screen for kinases during mouse 
cardiogenesis (Ruiz, Conlon et al. 1994). It was found to be up-regulated in the 
developing heart suggesting involvement in the process of cardiogenesis. Snf1lk is 50% 
identical to the protein SNF-1 found in yeast which is activated in response to nutrient 
stress. Later, a homolog of snf1lk was found in adrenal glands of rats that were fed high 
salt diet (Lin, Takemori et al. 2001).  
 
In humans, SIK1 gene is located on chromosome 21, while the two other genes SIK2 
and SIK3 are located on chromosome 11 (Katoh, Takemori et al. 2004). SIK1 and its 
two isoforms are 776 amino acids, 931 amino acids and 1263 amino acids long 
respectively. The three kinases, all have a highly conserved serine/threonine kinase 
domain at the N-terminal end, a SNF-1 domain in the middle and a site of potential 
serine phosphorylation at the C-terminal end. Of the three isoforms, SIK1 is found 
ubiquitously in human cells while SIK2 and SIK3 are found in specific tissues only. 
SIK homologs have been found in rats, mice and recently in chickens (Xia, Zhang et al. 
2000) and drosophila melanogaster (Adams, Celniker et al. 2000). A homolog to SIK, 
SOS2 is also found in plants where it is involved in responses to changes in salt 
concentration (Bertorello and Zhu 2009). The highly conserved forms of this kinase 
between species, suggest the importance of this protein. Indeed SIKs have been 
implicated in various intracellular pathways that are important for cell growth and 
survivability. 
3.2 STEROIDOGENESIS AND ADIPOGENESIS 
 
SIK1 is present in the adrenal cortex and its expression in cells is stimulated by 
increases in adrenocorticotropin (ACTH) (Jefcoate, Lee et al.), proceeding an increase 
in steroidogenic proteins. In addition, SIK1 was found to repress steroidogenic gene 
transcription (Okamoto, Takemori et al. 2004). ATCH treatment of mouse 
adrenocortical cells stimulates translocation of SIK1 from nucleus to cytoplasm 
(Okamoto, Takemori et al. 2004). This suggests that SIK1 might be involved in 
steroidogenesis in the adrenal cortex. SIK2 isoform expression has been found to be 
increased in adipocytes of type 2 diabetic mice (Horike, Takemori et al. 2003). During 
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normal conditions, insulin binding to the cell surface activates a tyrosine 
phosphorylation cascade leading to insulin receptor substrate-1 (IRS-1) activation and a 
lipogenic response in cultured 3T3-L1 adipocyte cells.  
3.3 ISCHEMIA 
 
Cerebral (brain) ischemia refers to insufficient blood flow to the brain which leads to 
oxygen deprivation causes energy starvation, decreased metabolic rates and death of 
cerebral tissue (infarction). Recently it has been established that SIK2 is involved in the 
protective molecular signaling pathway that is activated by glucose and oxygen 
starvation in cortical neuronal cell cultures (Cheng, Uchida et al.). Mice lacking SIK2 
have been shown to have a higher neuronal survival rate compared to the wild type 
mice in response to oxygen and glucose deprivation (Cheng, Uchida et al.). In the 
proposed intracellular pathway, CREB acts, via transducer of regulated CREB activity 
(TORC) and SIK2, activating neuronal pro-survival genes (Gallo and Iadecola). 
Briefly, in response to oxygen and glucose deprivation calmodulin-dependent kinase 1 
(CaMK1) phosphorylates SIK2 at Thr484 residue which leads to SIK2 degradation. 
Lack of SIK2 leads to dephosphorylation of TORC causing nuclear import of TORC 
where it activates CREB. CREB then increases the expression of pro-survival genes 
(Sasaki, Takemori et al.). Therefore, the SIK2-TORC-CREB pathway could be a 
potential target for protection of brain against ischemia and stroke. 
3.4 CELL SODIUM HANDLING 
 
Most cells are highly permeable to water and must maintain a regulated cell volume to 
be able to maintain the intact structure, avoiding shrinkage or swelling, in order to 
function normally. Very small ions and charged molecules will diffuse into the cell 
freely but large charged molecules will not. The negative charge inside the cells is 
caused by the negatively charged organic substances such as proteins and aminoacids. 
This will create an uneven distribution of negatively charged molecules and will cause 
an influx of ions and water into the cell. Cells maintain a membrane potential by 
keeping higher concentrations of sodium in the extracellular compartment while 
potassium is stored in the intracellular space. This balance is maintained by the NK 
pump. NK utilizes ATP to actively transport three sodium ions outwards across the 
membrane and at the same time transport two potassium ions from extracellular 
compartment inward against the ion gradient. The water that follows sodium out of the 
cell also helps the cell to prevent swelling.  
 
Besides being used in the vital cell volume regulation, sodium is vital to cell function as 
a signaling molecule in cardiac myocytes. It is involved in contraction, energy 
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metabolism and cardiac growth, as well as influencing the calcium signaling via the 
sodium-calcium exchanger (NCX). Because sodium is important in the development of 
hypertension and hypertrophy it is of importance to elucidate the precise molecular 
pathways involving sodium to be able to develop new therapeutic agents. The SIK 
network is involved in sodium regulation and signaling inside cells and in this thesis 
this network was the central focus, with the aim of better understanding the intracellular 
signaling that can cause hypertrophy and hypertension. 
 
 
 
 
 
 
 
 
   17 
4 HYPOTHESIS 
 
4.1 GENERAL AIM 
 
The aim of this study was to determine whether SIK1 could be involved in the blood 
pressure regulation and to elucidate the importance of the salt-inducible network during 
the development of cardiac hypertrophy. More specifically, we set out to examine the 
involvement of the salt-inducible kinase in the signaling cascade leading to the 
development of hypertension and examined whether the different isoforms of salt-
inducible kinase are implicated in the different intracellular mechanisms that can affect 
the development of cardiac hypertrophy independently of changes in BP. 
4.2 SPECIFIC AIMS 
4.2.1 Aim 1 
 
To examine whether salt-inducible kinase 1 affects Na+/K+-ATPase activity in vascular 
smooth muscle cells and endothelial cells and whether genetic variation within SIK1 
could affect blood pressure in humans. 
4.2.2 Aim 2 
 
To elucidate whether sodium could, via the salt-inducible kinase network affect the 
activation of transcription factors involved in the development of cardiac hypertrophy 
and whether sodium could affect myocyte growth independently of high blood 
pressure. 
4.2.3 Aim 3 
 
To determine whether salt and a genetic variation in the α-adducin gene are involved in 
the development of cardiac hypertrophy independently of sustained changes in blood 
pressure and whether salt-inducible kinase network mediates this effect. 
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5 MATERIALS AND METHODS 
 
5.1 CELL CULTURES 
 
The cardiac atrial cell line HL-1 was used as the experimental model for cardiac 
myocytes. HL-1 is a mouse atrial cell line that can be recovered from frozen stocks, be 
serially propagated in culture and still retain the biochemical and physiological 
properties of adult cardiomyocytes such as contraction and expression of cardiac 
specific markers. This cell line expresses the proteins found in adult cardiac myocytes 
such as a myosin heavy chain, skeletal actin, atrial natriuretic peptide and sarcomeric 
myosin (Claycomb, Lanson et al. 1998) among others. This cell line also expresses 
SIK1 and SIK2 isoforms (Popov, Venetsanou et al.). The cells were maintained at 37°C 
in an atmosphere of 5% CO2 and 95% air and cultured in Claycomb medium 
(Claycomb, Lanson et al. 1998) (Sigma), supplemented with 10% fetal bovine serum, 
100 units/ml penicillin and 100 μg/ml streptomycin, 1% L-glutamine, and 10 μM 
norepinephrine (Sigma). Cells were grown in flasks pre-coated with fibronectin [25 μg 
fibronectin (Sigma) in 2 ml of 0.02% gelatin (Sigma)].  
 
The A7r5 cell line was used as the experimental model for smooth vascular muscle 
cells. This cell type derives from rat aorta smooth muscle and possesses the properties 
of vascular smooth muscle cells such as expressing the creatine phosphokinase muscle 
type and being able to generate action potentials at some stage of the development 
(Kimes and Brandt 1976). The cells were from ATCC (American Type Culture 
Collection, Manassas California, USA) and were maintained at 37°C in atmosphere of 
5% CO2 and 95% air and cultured in Dulbecco’s modified Eagle’s medium (Gibco, 
Carlsbad, California, USA) supplemented with 10% fetal bovine serum, 100 units/ml 
penicillin and 100 μg/ml streptomycin. 
5.2 LEFT VENTRICLE MASS DETERMINATION 
 
Left ventricular mass in normotensive individuals has been found to be a predictor of 
development of hypertension (Devereux, de Simone et al. 1993). It is a strong predictor 
that reflects sodium intake and other pathophysiological factors affecting development 
of hypertension. Left ventricle mass was measured in 1792 participants of the MMP 
study who underwent echocardiography in the left lateral decubital position. All 
analyses were performed offline without any knowledge of the patients’ clinical status 
and interobserver and intraobserver variability were tested by two readers 
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independently analyzing images from a random subsample of participants. Detailed 
instrument and measurement descriptions can be found in Article I Methods section. 
5.3 SNP GENOTYPING 
 
Four populations were genotyped for the human SIK1 SNP rs3746951: Malmö Diet 
and Cancer study (15273 participants), Malmö Preventive Project (5144 participants), 
Stockholm cohort (1273 participants) and the Ohasama study (1162 participants). 
Illumina Infinium II Human 1M (Illumina, Inc., San Diego, California, USA) at SNP 
Technology Platform, Uppsala University was used for genotyping the Stockholm 
cohort and TaqMan methodology (assay C_3004267_10, Applied Biosystems) was 
used to genotype the Malmö and Ohasama cohorts. 
5.4 DETERMINATION OF NA+/K+-ATPASE ACTIVITY  
 
A7r5 VSMC grown in Petri dishes in standard A7r5 medium until 80% confluence 
were transfected with either the SIK1(15Gly) or SIK1 (15Ser) plasmids (7μg) for 8h in 
basal DMEM medium and allowed to express the proteins for 36h. Cells were then 
transferred into 24-well plates, with 70,000 cells/well for incubation overnight. 
Following this, the 86Rb+transport assay was performed as described elsewhere 
(Pedemonte, Pressley et al. 1997; Efendiev, Bertorello et al. 2002) to measure the 
Na+/K+-ATPase activity. 
5.5 IMMUNOHISTOCHEMISTRY 
 
Immunohistochemistry was performed on abdominal aorta samples obtained from 
patients at Karolinska Hospital undergoing elective surgery. Briefly, tissues were fixed 
with formaldehyde and embedded in paraffin. Rabbit antihuman SIK1 antibody (1 : 50) 
was used to stain for SIK1. Tissue slices were incubated overnight at 4°C after 
deparaffinizing and antigen retrieval treatment with DIVA decloaker according to the 
manufacturer’s instructions (Biocare Medical, Concord, California, USA). After 
washing in PBS, slides were incubated with a biotinylated horse antirabbit IgG (Dako 
A/S, Glostrup, Denmark) for 30 min at room temperature. Slides were then incubated 
with avidin–peroxidase complexes (ABC Elite Kit, Vector Labs, Burlingame, 
California, USA) for 30 min, followed by visualization with 3,30-diaminobenzidine 
tetrahydrochloride (Vector Labs). Isotypic rabbit IgG (Abcam, Cambridge, UK), used 
in the same concentration as for anti-SIK1 antibody, was used as a negative control for 
SIK1 staining. Slides were finally counterstained with Mayer’s hematoxylin 
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5.6 TAQMAN QUANTITATIVE REAL TIME PCR 
 
Total cellular RNA was isolated using E.Z.N.A. Total RNA Kit I (Omega Bio-Tek, 
Norcross, GA). RNA was quantified spectrophotometrically using a nanodrop 1000 
Spectrophotometer (Thermo Scientific) and total cDNA was synthesized from 0.5μg 
RNA in a polymerase reaction using RevertAid H Minus M-MuLV reverse 
transcriptase (Fermentas, Life Science, Vilnius, Lithuania). All assays and reagents for 
real-time quantitative PCR were obtained from Applied Biosystems (Foster City, CA). 
All assays were performed using the ABI Prism 7000 sequence detection system 
according to the manufacturer’s protocol, using five-point standard curves generated 
from 10-fold dilutions of purified PCR products. The results were expressed in 
arbitrary units or as percent change of units related to the levels of RPLPO mRNA 
expression for normalization. 
5.7 LUCIFERASE ASSAY 
 
Luciferase activity was determined in HL-1 cells transfected with NFAT-Luc vector 
(Clontech, Laboratories Inc., Palo Alto, CA), MEF2-Luc vector (Shin, Seoh et al. 
1999), BNP-Luc vector (obtained from Professor David Gardner), β-MHC-Luc vector 
(originated from Dr Robert MacLellan) in combination with either SIK1-WT 
(Sjostrom, Stenstrom et al. 2007), SIK1-K56M (Sjostrom, Stenstrom et al. 2007), 
SIK1-T322A (Sjostrom, Stenstrom et al. 2007), α-adducins (G460/S586 normotensive, 
W460/C586 hypertensive) (Efendiev, Krmar et al. 2004), SIK2-WT (Horike, Takemori 
et al. 2003), SIK2-K49M (Horike, Takemori et al. 2003), HDAC-WT (Takemori, 
Katoh Hashimoto et al. 2009), HDAC (S259A) (Takemori, Katoh Hashimoto et al. 
2009) or pRL-TK Renilla (Promega). Cells were plated into 24-well plates (70,000-
100,000 cells/well) and transient transfections were performed using lipofection 
method (LipofectAMINE 2000, Invitrogen) according to the manufacturers’ 
instructions. After incubations according to desired treatments and timing, the cell 
medium was removed and the reaction was stopped by washing the cells twice using 
ice-cold PBS and dissolved in 100 μl of luciferase assay buffer. The cell lysates were 
vortexed for 30 sec and incubated at –20 ºC for 5 min. Cells were further disrupted on a 
shaker for 30 min. Cell lysates (20 μl) were mixed with 100 μl of Luciferase Assay 
reagent (Promega, Madison, WI, USA) and the light produced was measured in a 
Luminometer (Turner Designs, Sunnyvale, CA, USA). For Renilla normalization Stop 
& Glo® Reagent (Promega, Madison, WI, USA) was added and the light emitted by 
Renilla luciferase was measured. Luciferase activity was expressed as the ratio between 
the light emitted by the luciferase-tagged plasmid and Renilla. Luciferase activity was 
also expressed as percentage change of the ratio between the light produced and the 
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protein concentration in the sample (RLU/mg of protein). Protein concentration in the 
cell lysates was determined using a commercial dye reagent (Bradford, BioRad). 
5.8 GENE EXPRESSION DETERMINATION FROM HUMAN BIOPSIES 
AND ANIMAL TISSUES 
 
Tissue from the intima/media layer of mammary artery (n=88) and heart (n=139) were 
collected from Swedish patients undergoing heart valve surgery (Paloschi, Kurtovic et 
al.). The intima/medial and adventitial layers of the mammary artery were separated by 
adventicectomy. Biopsies, heart tissue from transgenic mice and Milan rats were 
directly incubated with RNAlater (Ambion, Austin, TX) and homogenized with a 
FastPrep using Lysing Matrix D tubes (MP Biomedicals, Germany). Total RNA was 
isolated using Trizol (BRL-Life Technologies) and RNeasy Mini kit (Qiagen, Crawley, 
UK) including treatment with RNase-free DNase (Qiagen) according to manufacturer’s 
instructions. The quality of RNA was analyzed with an Agilent 2100 bioanalyzer 
(Agilent, Santa Clara, CA) and quantity was measured using a NanoDrop (Thermo 
Scientific, Waltham, MA). The RNA from human biopsies was hybridized and scanned 
at the Karolinska Institute microarray core facility. Affymetrix GeneChip® Human 
Exon 1.0 ST arrays and protocols were used (Affymetrix®, Santa Clara, CA). The raw 
cell files were preprocessed and log2 transformed using Robust Multichip Average 
normalization as implemented in the Affymetrix Power Tools 1.10.2 package apt-
probeset-summarize. All investigations were done on the core meta sets of meta probes 
provided by Affymetrix. The RNA from mice and rats tissues was analyzed using 
TaqMan 
5.9 IN VITRO SIK PHOSPHORYLATION 
 
Peptides for HDAC5 fragments (S259): LRKTASEPNL, S498: LSRTQSSPLP, 
S661:LGRTQSSPAA; bold S indicates the candidate for the phosphorylation site of 
SIK1; were expressed as GST-fusion protein and used as the substrate. E. coli-
expressed recombinant SIK1 (GST-SIK: 0.1 μg) was incubated with the substrates (0.1 
μg) in the presence of 1.0 μCi [γ32P]ATP at 25 °C for 20 min. The reaction was stopped 
by the addition of sample buffer. The peptides were separated by SDS-PAGE and 
identified by autoradiography. GST-Syntide2 peptide was used as a positive control. 
5.10 INTRACELLULAR PH DETERMINATION 
 
pH measurements were performed using trapped fluorescent indicator method with 
2’,7’-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF) as the fluorescent 
indicator. A non-charged, membrane-permeant derivative of BCECF, acetoxymethyl 
ester BCECF-AM was used to load a cell sample which then diffuses through the cell 
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membrane and is cleaved by cell esterases to form BCECF which then fluoresces 
according to the intracellular pH. Cells were grown in 96-well plates, as described 
previously (Gomes and Soares-da-Silva 2006). Cell culture medium was aspirated, and 
the cell monolayers were incubated for 30 min with 10 mM BCECF-AM at 37°C in 5% 
CO2-95% air atmosphere. Cells were placed in the sample compartment of a dual-
scanning microplate spectrofluorometer (Spectramax Gemini XS; Molecular Devices), 
and fluorescence was measured every 17 s alternating between 440 and 490 nm 
excitation at 535 nm emission, with a cut-off filter of 530 nm. The ratio of intracellular 
BCECF fluorescence at 490 and 440 nm was converted to intracellular pH (pHi) values 
by comparison with values from an intracellular calibration curve using the nigericin 
(10 μM) and high-K+ method (Gomes and Soares-da-Silva 2006; Pinto, Pinho et al. 
2008). 
5.11 DETERMINATION OF SIK1 AND SIK2 ACTIVITY  
 
A7R5 vascular smooth muscle cells were independently transfected with GST-SIK1-
15Gly or GST-SIK1-15Ser isoforms (GST-SIK1 either bearing the Gly or Ser at position 
15). After expression, SIK1 proteins were isolated. All samples were run on one and 
the same SDS-PAGE and Western Blot was performed. The membranes were probed 
with an antibody against phosphorylated (pT182) SIK1 residue (this phosphorylation 
site reflects activation of SIK1 and, hence, activity) and with a polyclonal antibody 
against SIK1 that recognize multiple epitopes in the protein (reflecting total amount of 
SIK1 on the blot). SIK1 activity was expressed as the ratio between the phosphorylated 
(pT182 antibody against phosphorylated SIK1) and the total amount of SIK1 expressed 
(SIK1 antibody), as previously described (Stenstrom, Takemori et al. 2009).  
HL-1 cells that had been transformed with pEBG-SIK2 (expression vector for GST-
fusion protein) (Horike, Takemori et al. 2003) were lysed with 1 ml of IP lysis buffer 
(Horike, Takemori et al. 2003). GST-SIK2 protein was purified with glutathione-
Sepharose column (GE-Healthcare). To detect SIK2 and phospho-SIK2 (pT175), anti-
SIK2 antibody and anti-phospho-SIK1 antibody (pT182) that recognize the pT175 
(phosphoaminoacid that reflects activation in SIK2 protein) were used. All samples 
were run on one and the same SDS-PAGE and WB was performed. The membranes 
were probed with an antibody against phosphorylated SIK1 and with a polyclonal 
antibody against SIK2 that recognize multiple epitopes in the protein (reflecting total 
amount of SIK2 on the blot). SIK2 activity was expressed as the ratio between the 
phosphorylated (pT182 antibody) to the total amount of SIK2 expressed. 
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5.12 BLOOD PRESSURE DETERMINATION IN ANIMALS  
 
Systolic blood pressure was measured in Milan normotensive and hypertensive rats by 
tail plethysmography (BP recorder, U. Basile, Varese, Italy) in conscious rats. The tail 
cuff method was used for measuring blood pressure in sik2+/+ and sik2-/- mice. After 
five minutes of applying the cuff to the mice tail, blood pressure variations were 
monitored using a digital recorder K2000ST as indicated by the manufacturer 
(Muromachi Kagaku Co. Ltd., Tokyo, Japan) (Matoba, Doyama et al. 2001). 
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6 RESULTS AND DISCUSSION 
 
The results of these studies revealed the importance of the SIK1 as a molecule involved 
in the BP regulation. SIK1 by itself or in combination with humoral factors could 
influence BP in different populations. Moreover, the SIK1 protein and the SIK1 
network were found to be implicated in the process leading to the activation of 
important transcription factors such as MEF2 and NFAT and several genes that are 
involved in CH development. The novel finding was that salt could, via the SIK 
network, influence the development of CH independently of BP in different mouse 
strain models and in vitro studies salt affected expression of genes associated with CH 
via the SIK network. Altogether these data support the theory that salt is an important 
factor affecting BP and independently of BP can influence the development of CH and 
that SIK network could be one of the key regulating pathways in the development of 
these pathological conditions. 
 
6.1 SALT-INDUCIBLE KINASE 1 INFLUENCES NA+,K+-ATPASE 
ACTIVITY IN VASCULAR SMOOTH MUSCLE CELLS AND 
ASSOCIATES WITH VARIATIONS IN BLOOD PRESSURE (ARTICLE 
I)  
 
Essential hypertension is a multifactorial condition that remains a major worldwide 
problem. Salt diet and genetic preconditions are thought to be some of the factors 
involved in development of essential hypertension. In kidneys and in vasculature a key 
enzyme involved in sodium regulation is Na+/K+-ATPase. Recently a novel salt-
inducible kinase 1 (SIK1) has been discovered that is involved in cell salt homeostasis 
and Na+/K+-ATPase activity regulation. An SNP in the coding region of human SIK1 
(rs3746951) is described where a change from amino acid C  T leads to a change in 
the protein product from glycine to serine. This SNP occurs at a high frequency of 0.25 
in the population. The sequence where this SNP is located bears very little similarity to 
SIK2 and SIK3 proteins meaning that if this change affects SIK1 function it would 
affect SIK1 dependent systems but not systems that are dependent on SIK2 and SIK3.  
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Figure 4. A schematic map of the rs3746951, the SIK isoforms and the location of the 
functional regions. rs3746951 is located next to the kinase domain of SIK1 protein. A 
substitution in human SIK1 gene, exon 3, (C  T) leads to amino acid change 15Gly  Ser in 
the final protein product. 
 
Therefore we hypothesized that this SNP could affect SIK1 function and SIK1 
dependent pathways and possibly influence sodium homeostasis, NK function and BP 
variations in humans. We started by examining the effect of the rs3746951 on SIK1 
activity in a cultured VSMC cell line derived from rat aortas. Transient overexpression 
of either the Gly15 or Ser15 variants of SIK1 lead to a significantly higher basal SIK1 
activity (using GST-isolation and Western Blot) in cells expressing the Ser15 compared 
to cells expressing the Gly15 variant. We then proceeded to examine the effect of the 
Ser15 variant on the NK activity. Using the 86Rb+transport assay we found that cells 
overexpressing the Ser15 variant had significantly increased NK activity compared to 
cells transiently expressing the Gly15 variant. Thus we demonstrated that higher SIK1 
activity in VSMC leads to higher NK activity.  
Following the biochemistry studies we proceeded to examine the effect of rs3746951 in 
different populations. Genotype-phenotype association studies between rs3746951 and 
BP were performed using several population-based cohorts (Stockholm study, MPP, 
MDC-CC and Ohasama studies). In additive models with the minor allele as coded 
(rs3746951 T-allele), the point estimates of the β-coefficient were negative in all 
study groups, and statistically significant in the largest study (MPP). Meta-analysis of 
the results from all four study groups was then performed, with test of effect estimate, 
ES of 0, resulting in z of 2.78, P value of 0.005 for SBP, and z of 3.06, P value of 
0.002 for DBP, meaning that the presence of the rs3746951 is associated with both 
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lower SBP and DBP pressures. However, there was no significant association between 
the rs3746951 and hypertension. Because left ventricular mass reflects the 
pathophysiology of hypertension we examined association between left ventricle mass 
and BP in a sub set of the MPP study. The Ser15 variant was significantly associated 
with lower LV mass which confirmed the previous results of lower BP and rs3746951 
association.  
Our group has previously shown that SIK1 is involved in a salt-sensitive network that 
affects NK activity (Sjostrom, Stenstrom et al. 2007). The Gly  Ser15 could change 
the way SIK1 interacts with other proteins involved in this network or involve other 
unknown partner molecules that cause higher SIK1 activity. High NK activity means 
that more sodium is excreted from VSMC when the cells are expressing the Ser15 
variant. This could set a lower vascular tone through lower activity of the NCX which 
leads to lower concentrations of calcium ions in the cell and cause cell relaxation. The 
precise molecular pathways and how the rs3746951 is affecting the NK are still to be 
elucidated however; since this SNP is adjacent to the kinase region of SIK1 one could 
speculate that rs3746951 influences SIK1 protein structure or/and its kinase activity 
which in turn could have an effect on NK activity. Alternative explanations are that 
higher NK activity can lead to lower BP levels by making vasculature less susceptible 
to OLF that are released at increased sodium levels or, that the higher activity of NK in 
endothelial cells may lead to hyperpolarization which decreases release of endothelin 
resulting in decreased BP. 
Data generated from animal studies and human studies indicate that the genetic factor 
contributing to hypertension accounts for 30-50%. Because essential hypertension 
involves small effects of multiple genes and environmental factors it is not surprising 
that the effect of rs3746951 on hypertension was small and not significant. However, 
these results point to the SIK1 as a possible candidate gene that could be involved in 
BP regulation.  
A caveat in this study was the lack of data describing levels of salt intake in all four 
populations. However, rs3746951 affected the SBP and DBP in both Japanese and 
Swedish populations, which is of importance because average levels of salt intake in 
Japan are higher than in Sweden (11.7 and 9 g/day respectively at the time of 
recruitment of participants) (Brown, Tzoulaki et al. 2009; Ogihara, Kikuchi et al. 
2009). To further examine the effect of rs3746951 on BP, population-based studies 
with documented sodium intake / sodium excretion would be necessary. The 
importance of rs3746951 in the kidneys can also be examined since rs3746951 is 
affecting NK activity and the NK is affecting sodium re-absorption rate in the kidneys. 
In summary, in this article we confirmed the importance of SIK1 for the BP regulation 
by both population-based studies and in cell based experiments. Rs3746951 appears to 
be affecting BP regulation possibly in combination with humoral factors, salt intake 
and lifestyle.  
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6.2 INCREASES IN INTRACELLULAR SODIUM ACTIVATE 
TRANSCRIPTION AND GENE EXPRESSION VIA THE SALT-
INDUCIBLE KINASE 1 NETWORK IN AN ATRIAL MYOCYTE CELL 
LINE (ARTICLE II) 
 
Cardiac hypertrophy means enlargement of the heart due to increased size of cells and 
is divided in two general forms: pathological hypertrophy and physiological 
hypertrophy. Physiological hypertrophy is a natural response to increased work-load on 
the heart such as heavy exercising or pregnancy and is reversible. Pathological 
hypertrophy is not reversible unless treated and results in abnormal mechanical stress 
usually caused by valve stenosis or hypertension. Molecular pathways that are initiated 
during pathological hypertrophy are somewhat similar to those involved in 
physiological hypertrophy, but do include different intracellular signaling systems. 
Hypertension is one of the major causes of CH, however, in certain animal models salt 
intake can result in hypertrophy without significant increases in BP and without 
involvement of the humoral factors and the RAAS system (Schmieder, Messerli et al. 
1988; Frohlich, Chien et al. 1993). SIK1 has been shown to be involved in sodium 
regulation in cells (Sjostrom, Stenstrom et al. 2007) and its expression levels increase in 
adrenal medullas of rats that are fed high salt diet. SIK1 has also been coupled with 
transcription factors that are involved in the development of CH such as CREB 
regulation via the TORC-SIK1 cascade (Takemori, Kajimura et al. 2007) and class II 
HDAC phosphorylation which increases MEF2 activity (Berdeaux, Goebel et al. 2007). 
Therefore we hypothesized that salt could activate genes and transcription factors that 
are involved in the development of CH independently of increases in BP and that SIK1 
could be a key mediator in such system.  
We set out to establish whether transient sodium increases in cultured cells could affect 
expression levels of BNP, β-MHC and α-MHC. These genes have been coupled with 
the development of hypertrophy. To this end, cultured atrial cells (HL-1) were used. 
These cells can be serially passaged, are able to contract and share biochemical 
properties of the adult cardiac myocytes (Claycomb, Lanson et al. 1998). Intracellular 
sodium increase was achieved using sodium ionophore monensin (Efendiev, Bertorello 
et al. 2002). After performing either Luciferase or TaqMan assays we discovered that 
all of the examined genes had a time dependent increase in response to increased 
sodium concentrations.  
Next, we proceeded to establish whether the transcription factor (TF) MEF2, which is 
commonly associated with the induction of hypertrophic genes, was also activated by 
sodium. MEF2 is a TF that is relevant for normal cardiac growth and has also been 
coupled with activation of hypertrophic genes. Therefore we examined the response of 
MEF2 to sodium. Cells transiently expressing the luciferase-tagged MEF2 vector had a 
significant increase in MEF2 activity in response to sodium induced both by monensin 
and a sodium ion channel activator veratridine.  
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SIK1 has been recognized as critical molecule for myocardium development (Romito, 
Lonardo et al. ; Ruiz, Conlon et al. 1994) and is also involved in a sodium-sensitive 
pathway that regulates NK activity in cells (Sjostrom, Stenstrom et al. 2007). We 
hypothesized that SIK1 could mediate the response of BNP and SkA hypertrophic genes 
to sodium. After establishing that SIK1 mRNA levels had similar increases in response 
to sodium as the hypertrophic genes, we used SIK1 specific siRNA to knock down 
SIK1 and examined BNP and SkA mRNA levels using TaqMan assay. Knocking down 
SIK1 led to a significant decrease of the hypertrophic genes. To further ascertain SIK1 
as the mediatory molecule, we double-transfected HL-1 cells with luciferase tagged 
plasmids MEF2, BNP, β-MHC and with either SIK1-WT or SIK1-K56M mutant 
lacking the kinase activity. Cells expressing the mutant had demonstrated significantly 
lower luciferase activity of MEF2, BNP and β-MHC in response to monensin.  
We then confirmed the association between hypertrophic genes and SIK1 by 
performing correlation studies in human heart biopsies (in both mammary artery tissue 
and heart tissue). SIK1 was found to be positively and significantly correlated with β-
MHC, BNP and SkA genes (with exception of SkA in the mammary artery tissue). How 
does SIK1 mediate the sodium signals to the hypertrophic genes? Many of the 
intracellular pathways that lead to the development of hypertrophy in heart cells are 
transduced by calcium signaling (Frey and Olson 2003). Sodium influx can induce 
activation of the reverse mode NCX and thereby increase the concentration of calcium 
ions in the cell. Our group has previously demonstrated that SIK1 can be activated by 
influx of sodium resulting in activation of reverse mode of NCX and subsequent CaMK 
phosphorylation of SIK1 (Stenstrom, Takemori et al. 2009). We tested the dependence 
of MEF2 on calcium in HL-1 cells after transfecting the cells with luciferase tagged 
MEF2 plasmid. This was done in three separate experiments: by blocking NCX 
channels, by quenching intracellular calcium and by inhibiting CaMKII. In response to 
monensin, all three experiments led to a significantly lower MEF2 luciferase activity 
when the calcium pathway was abrogated.  
The last step in elucidating the pathway from sodium influx to activation of 
hypertrophy genes was examining the link between SIK1 and MEF2. It has been 
previously demonstrated that SIK1 phosphorylates class II HDAC (Berdeaux, Goebel 
et al. 2007). Class II HDAC binds to MEF2 directly in the nucleus and represses its 
activity. Phosphorylation of HDAC leads to its dissociation from MEF2 and 
translocation from the nucleus. We tested whether transient increases of sodium could 
activate MEF2 in presence of class II HDAC specific blocker or in cells that transiently 
expressed HDAC lacking SIK1 phosphorylation domain. Cells that were pre-treated 
with the class II HDAC inhibitor or expressing the HDAC mutant had significantly 
lower MEF2 luciferase activity in response to monensin compared to cells without the 
inhibitor or expressing the wild type HDAC.  
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Influx of sodium induced by monensin, lead to a concomitant influx of calcium ions via 
the reverse mode of NCX. This activated CaMKII and lead to phosphorylation of SIK1 
and subsequent phosphorylation of class II HDAC. HDAC dissociates from MEF2 
which then activates genes associated with CH: BNP, SkA, β-MHC and α-MHC. As 
many reports indicate, transcription factors associated with CH often interact with each 
other to promote gene transcription. NFAT is a critical transcription factor involved in 
development of CH. NFAT can bind to GATA4 and activate transcription of BNP 
(Morimoto, Hasegawa et al. 2001). NFAT can also bind to MEF2 and enhance its 
activity in response to calcineurin (van Oort, van Rooij et al. 2006). Therefore we 
hypothesized that NFAT could act together with MEF2 in response to increased sodium 
concentrations. We performed transfection experiments where cells were expressing 
luciferase-tagged NFAT plasmid and were co-transfected with either the SIK1-WT or 
SIK1-K56M mutant. As expected, there was significantly lower luciferase activity of 
NFAT if cells were expressing the SIK1 mutant compared to cells expressing the SIK-
WT. Similarly to MEF2, the NFAT luciferase activity was blocked by the class II 
HDAC inhibitor or by cells expressing the HDAC mutant lacking the SIK1 
phosphorylation site for SIK1.  
 
Usually α-MHC is observed to be down-regulated during the development of 
pathological hypertrophy (Kinugawa, Yonekura et al. 2001). However, as in the case of 
calcineurin-mediated hypertrophy, calcineurin inhibitor MCIP can affect molecular 
pathways of both physiological and pathological hypertrophies (Rothermel, McKinsey 
et al. 2001; Hill, Rothermel et al. 2002) suggesting that even if the two hypertrophies 
differ somewhat at the molecular signaling level, certain genes and pathways may be 
involved in both forms of hypertrophy. 
It has been shown that by inhibiting MEF2, hypertrophy can be suppressed (Lu, 
McKinsey et al. 2000). However the suggested signaling mechanism affecting MEF2 
was mediated by CaMK and calcium. Here we demonstrate that sodium could be 
responsible for increasing MEF2 activity. Therefore we not only confirmed previous 
findings that calcium is involved in the signal transduction that activates MEF2 and CH 
genes, but also discovered that sodium could be an upstream regulator of these genes. 
There have not been any reports indicating that HDACs can bind to NFAT, however, 
because the MEF2 and NFAT can co-activate hypertrophic genes it is plausible that 
SIK1 phosphorylation of HDAC lead to binding of MEF2 to NFAT or vice-versa 
thereby promoting gene transcription. There is also a phosphorylation consensus 
sequence for SIK1 on NFAT which means SIK1 could phosphorylate both HDAC and 
NFAT directly. 
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Figure 5. A schematic representation of the way that sodium might affect the hypertrophic 
genes. Increases in intracellular sodium lead to concomitant increases in intracellular calcium 
via the reverse mode of NCX. Increased calcium concentration activates CaMK which 
phosphorylates SIK1. The activated SIK1 phosphorylates class II HDAC which then dissociates 
from MEF2 and translocates from the nucleus. MEF2 activity increases and is able to activate 
genes that are associated with CH. Whether MEF2 somehow activates NFAT or whether SIK1 
directly phosphorylates NFAT is yet unclear. 
6.3 GENETIC PREDISPOSITION OR HIGH SALT INTAKE CAUSE 
CARDIAC HYPERTROPHY THROUGH ACTIVATION OF SIK2 
INDEPENDENTLY OF BLOOD PRESSURE LEVELS (ARTICLE III) 
 
Because we demonstrated that SIK1 could be a mediator molecule in response to 
sodium we hypothesized that other SIK isoforms could also be involved in regulation 
of CH genes and transcription factors independently of changes in arterial BP. It is also 
possible that other SIK isoforms are involved in cellular response to the changes in 
sodium concentrations. Adducin is a cytoskeletal protein that is involved in spectrin-
actin binding, controls the rate of actin polymerization and is dependent on calcium 
(Bianchi, Ferrari et al. 2005). It consists of three subunits encoded by genes ADD1 (α-
adducin) ADD2 (β-adducin) and ADD3 (γ-adducin). Several association studies have 
linked an SNP in the ADD1 and hypertension in different populations (Cusi, Barlassina 
et al. 1997). Same alteration in α-adducin gene has been implicated in development of 
hypertension through increased renal re-absorption of sodium (Bianchi, Tripodi et al. 
1994). Since CH could also be affected by genetic predisposition we hypothesized that 
adducin could be a gene that affects SIK proteins and influence the development of CH. 
We hypothesized that adducin could be involved in CH development independently of 
changes in BP. 
To examine the effect of adducin on CH we used a strain of Milan hypertensive rats 
(MHS) with a mutation in the α-adducin gene (Add1 Phe316Tyr) (Bianchi 2005) that 
causes the rats to develop hypertension with age. The rats that were used were 30 days 
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old and were in a period before they develop hypertension (MHS-pre). These rats had, 
as expected, normal BP when compared to normotensive controls but had significantly 
higher expression of Nppb and β-mhc genes that are coupled with hypertrophy. 
Moreover, the expression of SIK2 was higher in the MHS-pre rats compared to 
normotensive control rats. These initial results suggested that CH genes were not 
dependent on BP and also that SIK2 could be involved in CH development. 
Surprisingly SIK1 levels were not increased in contrast to our previous finding that 
SIK1 mediated the increase in NPPB and MHC gene expression. However the system 
that was used in the previous study was different (cultured atrium cells) and it is 
possible that both SIK1 and SIK2 are relevant, depending upon the cell system. 
Because SIK2 levels were increased in the MHS-pre rats that have a hypertensive form 
of adducin we performed adducin specific knockdown in HL-1 cells using siRNA. The 
knockdown of α-adducin lead to a significant decrease of SIK2 levels and knockdown 
of γ-adducin lead to a reduction of SIK2 but not a significant one. To confirm the 
dependency of SIK2 on adducin we analyzed whether there were any correlations 
between SIK2 and adducin isoforms in biopsies from human subjects undergoing heart 
valve surgery. The results revealed that there was indeed a positive and significant 
correlation between SIK2 and γ- and α-adducins. 
We further explored the dependency of the CH genes on adducin and SIK2 by 
analyzing correlations between the CH markers and SIK2 and adducins in the same 
biopsies. There were positive and significant correlations between SIK2 and the TF 
MEF2, β-MHC and ACTA1. In addition, γ- and α-adducins were positively correlated 
with MEF2, β-MHC and ACTA1. Based on these results we speculated that the 
presence of the hypertensive form of adducin could, via SIK2 trigger activation of 
MEF2 and subsequently lead to an elevation of CH-associated genes. Surprisingly 
SIK2 levels were not different in HL-1 cells transiently expressing either normotensive 
or hypertensive form of α-adducin. The SIK2 activity, whereas higher in the cells with 
hypertensive form of α- adducin, did not reach a statistical significance. This could 
mean that the experimental system (MHS rats or in vitro studies) play a role. We 
examined whether the CH markers and MEF2 expression was mediated by SIK2 in 
HL-1 cells expressing either the normotensive or hypertensive form of α-adducin 
together with either the SIK2 WT or a SIK2 mutant K49M lacking kinase activity and 
found that HL-1 cells expressing SIK2 WT and the hypertensive form of α-adducin had 
significantly increased MEF2, NPPB and β-MHC luciferase activities compared to the 
cells expressing normotensive variant. This effect was absent in cells expressing the 
SIK2 mutant which further confirmed that SIK2 mediates the effect of α-adducin on 
genes coupled with CH. 
To further elucidate the importance of SIK2 on the CH development and its possible 
function as a sensor of sodium imbalances, we used transgenic mice with ablated SIK2. 
Four month old wild type mice that were fed high salt diet (1% saline) had a 
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significantly increased heart weight compared to control animals fed tap water. This 
increase was absent in sik2-/- mice which were fed the same salt diet.  
These results demonstrate that SIK2 is one of the key molecules involved in salt-
dependent CH. In our previous article we demonstrated that SIK1 was the key protein 
mediating the effects of increased salt on MEF2 and NFAT and on the genes associated 
with CH. However, these results demonstrate that in rats and mice SIK2, not SIK1 is 
responsible for the events that can cause CH. It is possible that SIK1 could have a 
compensatory effect when the SIK2 is absent and a double knockout/overexpression of 
SIK1 and SIK2 would be ideal to examine whether SIK1 and SIK2 contribute equally 
to the development of CH in different experimental models. Nevertheless it appears 
that SIK2 is an important mediator of sodium effect on the development of CH. These 
results also indicate that the presence of the hypertensive form of α-adducin per se 
represents a risk factor for the development of CH. The α-adducin but not γ-adducin 
appears to be a regulator of SIK2 expression and activity. The mechanism by which 
adducin controls SIK2 activity or expression remains to be explored. 
   33 
7 SUMMARY AND CONCLUSION 
 
Recently, salt-inducible kinase 1 and its isoforms have emerged as proteins 
participating in several intracellular mechanisms, involving a wide range of pathways 
such as cell cycle regulation, cell sodium homeostasis and steroidogenesis and 
adipogenesis. The projects presented in this dissertation were aimed towards exploring 
the involvement of the salt-inducible kinases and SIK network in the development of 
hypertension and hypertrophy.  
The findings presented in this thesis provide further support for the theory that 
sustained changes in BP and subsequent mechanical load on the heart are not necessary 
for the development of CH. This thesis also confirms previous knowledge about the 
sodium effect on the BP and suggests the importance of SIK1 in the development of 
hypertension. 
 
In Article I we demonstrated that genetic variation within SIK1 affects systolic and 
diastolic blood pressure in different populations, affects left ventricular mass and 
increases the Na+/K+-ATPase activity in cultured vascular smooth muscle cells. We 
conclude that SIK1, possibly in combination with humoral and life-style factors, is 
important for BP regulation and could be a potential drug target. 
 
In Article II we explored the possibility of SIK1 being involved in a process that up-
regulates genes and transcription factors coupled to development of hypertrophy in 
cultured myocytes in response to salt. We found that SIK1 mediated the effect of 
sodium on the gene expression and protein levels of key transcription factors and genes 
involved in development of CH. We conclude that it is plausible that hypertrophy can 
develop without sustained increases in BP in response to salt and that SIK network is a 
key pathway involved in this process. 
 
In Article III we utilized different experimental systems to prove that salt and a 
mutation within cytoskeletal protein α-adducin per se can affect development of CH 
independently of high BP. Human, rat, mouse models as well as cell based 
experiments, confirmed our theory. We conclude that SIK2 mediates the effect of α-
adducin on the transcription factor MEF2 and genes coupled with hypertrophy and that 
blocking SIK2 could provide novel therapeutic approach to prevent CH in salt-sensitive 
individuals. 
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